Shanghai Haishun New Pharmaceutical Packaging Materials Co., Ltd. 2025 Annual Report of Independent Director (Guo Xun)
As an independent director of Shanghai Haishun New Pharmaceutical Packaging Materials Co., Ltd. (hereinafter referred to as the "Company"), in 2025, I strictly followed the requirements of laws and regulations such as the "Company Law of the People's Republic of China," the "Securities Law of the People's Republic of China," the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 2 - Standardized Operation of GEM Listed Companies," the "Articles of Association," and the "Work System for Independent Directors of the Company." I diligently performed my duties, acted diligently and responsibly, promoted the standardized operation of the Company, and protected the interests of all shareholders, especially small and medium shareholders, by fully leveraging the role of independent directors. The following is a report on my performance as an independent director of the Company in 2025:
I. Basic Information of Independent Director
I, Guo Xun, am a Chinese national with no overseas residency. I was born in September 1972 and hold a postgraduate degree. I previously served as the Asia Pacific Business Director for Silmar Corporation and Aptar Corporation, Deputy Secretary-General of the China Pharmaceutical Packaging Association, and Vice President of the Suzhou Industrial Park Huiyu Pharmaceutical Packaging Technology Research Institute. I have served as an independent director of the Company since June 17, 2024.
During the reporting period, my position complied with the provisions on independence in the "Administrative Measures for Independent Directors of Listed Companies," and there were no circumstances affecting my independence.
II. Attendance at Board Meetings and Shareholder Meetings
In 2025, with a diligent and responsible attitude, I actively participated in the board meetings convened by the Company, carefully reviewed meeting materials, actively participated in discussions on various agenda items, and put forward reasonable suggestions, playing a positive role in the correct decision-making of the board of directors. In 2025, the convening and holding of the Company's board meetings and shareholder meetings met statutory requirements, and major matters underwent relevant approval procedures. I voted in favor of all proposals at the board meetings, with no opposing or abstaining votes.
I attended 13 board meetings and 2 shareholder meetings convened by the Company in 2025. The attendance situation is as follows:
| Number of Board Meetings to Attend | Number of Board Meetings Attended | Number of Board Meetings Attended in Person | Number of Board Meetings Attended by Proxy | Number of Board Meetings Missed | Number of Shareholder Meetings Convened | Number of Shareholder Meetings Attended |
|---|---|---|---|---|---|---|
| 13 | 13 | 13 | 0 | 0 | 2 | 2 |
III. Communication with the Internal Audit Department and Accounting Firm
During the reporting period, I actively communicated with the Company's internal audit department and accounting firm, diligently performing my duties. I conscientiously listened to the work reports of the Company's audit department, including the annual internal audit work plan and internal audit work reports, and promptly understood the progress of key work items of the audit department. I guided and supervised the establishment and implementation of the internal audit system, effectively improving the Company's risk management level. Regarding the annual audit work, I actively communicated with the annual auditors, understood the audit scope, audit strategies, audit work arrangements, and key audit matters, continuously paid attention to the progress of the audit work, actively coordinated on issues found during the audit process, and ensured that the Company's annual audit work was strictly carried out according to the plan.